Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 Combined With Epirubicin in Extensive Small Cell Lung Cancer After First-line Treatment Failure
NCT03755115Phase 2
Key facts
- Status
- Unknown
- Start
- Feb 2019
- Primary completion
- Oct 2019
- Countries
- 1
- Sponsor
- Henan Cancer Hospital
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- camrelizumab
- Conditions
- small cell lung cancer (SCLC)
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in small cell lung cancer (SCLC), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Epirubicin plus SHR1210
Epirubicin + SHR-1210 combination followed by SHR-1210 maintenance
03
Who it enrols
Patients aged 18-75 with extensive small cell lung cancer who failed first-line treatment, with ECOG PS 0-1, expected survival >= 3 months, adequate organ function, and no prior anti-PD-1/L1 or CTLA4 therapy.
04
Endpoints
Primary
Objective Response Rate
Secondary
Progression-Free Survival
Disease Control Rate
Overall Survival
Adverse Events
Characteristic antigen on the surface of immunogenic dead cells
Beyond the preview
Go deeper on NCT03755115.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755115.